Abstract
Spinal muscular atrophy (SMA) is an autosomal recessive disease caused in most cases (95%) by a homozygous deletion of exons 7 and 8 of the survival motor neuron gene 1 (SMN1). SMN2 is consider a “back up” gene and the number of SMN2 copies determines the clinical phenotype. It is classified as types 0–4 depending on the age of onset and maximal motor function achieved. Clinically these patients have proximal and distal weakness, as well as areflexia. Diagnosis of SMA consists of molecular genetic testing with targeted mutation analysis of the SMN1 gene and copy number analysis of the SMN2 gene. Muscle biopsy is becoming increasingly uncommon; if done, it shows islands of markedly hypertrophic type 1 fibers floating in a sea of small mixed type 1 and 2 fibers in SMA type 1 and type 2. Management involves a multidisciplinary approach. Currently, Nusinersen is the only treatment approved by FDA for SMA. There are several therapeutic molecules under development, targeting other mechanisms of the disease. The prognosis for these patients is rapidly changing with the new therapy development.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Prior TW, Finanger E. Spinal Muscular Atrophy. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. GeneReviews®. Seattle (WA): University of Washington; 1993.
Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy (SMA). Hum Genet. 2002;111(6):477–500.
Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Eur J Hum Genet. 2012;20(1):27–32.
Darras BT. Spinal muscular atrophies. Pediatr Clin N Am. 2015;62(3):743–66.
Kolb SJ, Kissel JT. Spinal Muscular Atrophy. Neurol Clin. 2015;33(4):831–46.
Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 2012;11(5):443–52.
Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve. 2015;51(2):157–67.
Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103–15.
Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28(3):197–207.
Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713–22.
Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J. Nusinersen vs. Sham control in infantile- onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723–32.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Castro, D.P., Cai, C., Jacob Paul, D. (2020). A 3-Month-Old Boy with Generalized Hypotonia, Weakness, Pneumonia and Respiratory Failure. In: Zhou, L., Burns, D., Cai, C. (eds) A Case-Based Guide to Neuromuscular Pathology. Springer, Cham. https://doi.org/10.1007/978-3-030-25682-1_31
Download citation
DOI: https://doi.org/10.1007/978-3-030-25682-1_31
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-25681-4
Online ISBN: 978-3-030-25682-1
eBook Packages: MedicineMedicine (R0)